435 related articles for article (PubMed ID: 33298102)
1. Prophylactic, single-drug cardioprotection in a comparative, experimental study of doxorubicin-induced cardiomyopathy.
Lódi M; Bánhegyi V; Bódi B; Gyöngyösi A; Kovács Á; Árokszállási A; Hamdani N; Fagyas M; Édes I; Csanádi Z; Czuriga I; Kisvárday Z; Lekli I; Bai P; Tóth A; Papp Z; Czuriga D
J Transl Med; 2020 Dec; 18(1):470. PubMed ID: 33298102
[TBL] [Abstract][Full Text] [Related]
2. Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy.
Lódi M; Priksz D; Fülöp GÁ; Bódi B; Gyöngyösi A; Nagy L; Kovács Á; Kertész AB; Kocsis J; Édes I; Csanádi Z; Czuriga I; Kisvárday Z; Juhász B; Lekli I; Bai P; Tóth A; Papp Z; Czuriga D
J Transl Med; 2019 Jul; 17(1):229. PubMed ID: 31324258
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice.
Oronsky B; Ao-Ieong ESY; Yalcin O; Carter CA; Cabrales P
Mol Pharm; 2019 Jul; 16(7):2929-2934. PubMed ID: 31038318
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotective Effect of Phenytoin on Doxorubicin-induced Cardiac Toxicity in a Rat Model.
Razmaraii N; Babaei H; Mohajjel Nayebi A; Asadnasab G; Ashrafi Helan J; Azarmi Y
J Cardiovasc Pharmacol; 2016 Mar; 67(3):237-45. PubMed ID: 26544684
[TBL] [Abstract][Full Text] [Related]
5. The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity.
Akolkar G; Bhullar N; Bews H; Shaikh B; Premecz S; Bordun KA; Cheung DY; Goyal V; Sharma AK; Garber P; Singal PK; Jassal DS
Cardiovasc Ultrasound; 2015 Apr; 13():18. PubMed ID: 25889218
[TBL] [Abstract][Full Text] [Related]
6. β-Caryophyllene, a natural bicyclic sesquiterpene attenuates doxorubicin-induced chronic cardiotoxicity via activation of myocardial cannabinoid type-2 (CB
Meeran MFN; Al Taee H; Azimullah S; Tariq S; Adeghate E; Ojha S
Chem Biol Interact; 2019 May; 304():158-167. PubMed ID: 30836069
[TBL] [Abstract][Full Text] [Related]
7. Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity.
Hullin R; Métrich M; Sarre A; Basquin D; Maillard M; Regamey J; Martin D
Cardiovasc Res; 2018 Feb; 114(2):272-281. PubMed ID: 29016737
[TBL] [Abstract][Full Text] [Related]
8. The Cardioprotective Role of Flaxseed in the Prevention of Doxorubicin- and Trastuzumab-Mediated Cardiotoxicity in C57BL/6 Mice.
Asselin CY; Lam A; Cheung DYC; Eekhoudt CR; Zhu A; Mittal I; Mayba A; Solati Z; Edel A; Austria JA; Aukema HM; Ravandi A; Thliveris J; Singal PK; Pierce GN; Niraula S; Jassal DS
J Nutr; 2020 Sep; 150(9):2353-2363. PubMed ID: 32510147
[TBL] [Abstract][Full Text] [Related]
9. Effect of ghrelin on VEGF-B and connexin-43 in a rat model of doxorubicin-induced cardiomyopathy.
Elhadidy MG; Elmasry A; Rabei MR; Eladel AE
J Basic Clin Physiol Pharmacol; 2019 Nov; 31(1):. PubMed ID: 31730522
[TBL] [Abstract][Full Text] [Related]
10. α-Linolenic acid attenuates doxorubicin-induced cardiotoxicity in rats through suppression of oxidative stress and apoptosis.
Yu X; Cui L; Zhang Z; Zhao Q; Li S
Acta Biochim Biophys Sin (Shanghai); 2013 Oct; 45(10):817-26. PubMed ID: 23896563
[TBL] [Abstract][Full Text] [Related]
11. Vitamin C mitigates oxidative/nitrosative stress and inflammation in doxorubicin-induced cardiomyopathy.
Akolkar G; da Silva Dias D; Ayyappan P; Bagchi AK; Jassal DS; Salemi VMC; Irigoyen MC; De Angelis K; Singal PK
Am J Physiol Heart Circ Physiol; 2017 Oct; 313(4):H795-H809. PubMed ID: 28710069
[TBL] [Abstract][Full Text] [Related]
12. Comparing Flaxseed and Perindopril in the Prevention of Doxorubicin and Trastuzumab-Induced Cardiotoxicity in C57Bl/6 Mice.
Eekhoudt CR; Bortoluzzi T; Varghese SS; Cheung DYC; Christie S; Eastman S; Mittal I; Austria JA; Aukema HM; Ravandi A; Thliveris J; Singal PK; Jassal DS
Curr Oncol; 2022 Apr; 29(5):2941-2953. PubMed ID: 35621631
[TBL] [Abstract][Full Text] [Related]
13. Paroxetine mitigates cardiac remodelling by doxorubicin and increases survival.
Kosić M; Nešić Z; Glumac S; Vasić M; Pajović V; Savić B; Japundžić-Žigon N
Biomed Pharmacother; 2022 Jan; 145():112411. PubMed ID: 34781149
[TBL] [Abstract][Full Text] [Related]
14. A Novel Angiotensin Type I Receptor Antagonist, Fimasartan, Prevents Doxorubicin-induced Cardiotoxicity in Rats.
Chang SA; Lim BK; Lee YJ; Hong MK; Choi JO; Jeon ES
J Korean Med Sci; 2015 May; 30(5):559-68. PubMed ID: 25931786
[TBL] [Abstract][Full Text] [Related]
15. Protective Effect of Acetyl-L-Carnitine Against Doxorubicin-induced Cardiotoxicity in Wistar Albino Rats.
Dundar HA; Kiray M; Kir M; Kolatan E; Bagriyanik A; Altun Z; Aktas S; Ellidokuz H; Yilmaz O; Mutafoglu K; Olgun N
Arch Med Res; 2016 Oct; 47(7):506-514. PubMed ID: 28262191
[TBL] [Abstract][Full Text] [Related]
16. The Lack of Synergy between Carvedilol and the Preventive Effect of Dexrazoxane in the Model of Chronic Anthracycline-Induced Cardiomyopathy.
Szponar J; Ciechanski E; Ostrowska-Lesko M; Gorska A; Tchorz M; Dabrowska A; Dudka J; Murias M; Kowalczyk M; Korga-Plewko A; Mandziuk S
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373350
[TBL] [Abstract][Full Text] [Related]
17. Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane.
Della Torre P; Mazué G; Podestà A; Moneta D; Sammartini U; Imondi AR
Cancer Chemother Pharmacol; 1999; 43(2):151-6. PubMed ID: 9923821
[TBL] [Abstract][Full Text] [Related]
18. Enoxaparin attenuates doxorubicin induced cardiotoxicity in rats via interfering with oxidative stress, inflammation and apoptosis.
Shaker RA; Abboud SH; Assad HC; Hadi N
BMC Pharmacol Toxicol; 2018 Jan; 19(1):3. PubMed ID: 29321061
[TBL] [Abstract][Full Text] [Related]
19. Crocin treatment prevents doxorubicin-induced cardiotoxicity in rats.
Razmaraii N; Babaei H; Mohajjel Nayebi A; Assadnassab G; Ashrafi Helan J; Azarmi Y
Life Sci; 2016 Jul; 157():145-151. PubMed ID: 27297631
[TBL] [Abstract][Full Text] [Related]
20. Screening for
Chakouri N; Farah C; Matecki S; Amedro P; Vincenti M; Saumet L; Vergely L; Sirvent N; Lacampagne A; Cazorla O
Theranostics; 2020; 10(18):8130-8142. PubMed ID: 32724462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
